Evidence map›Paper›PMID 39381587›Full record

ReviewAPL bioengineering2024

Heterojunction semiconductor nanocatalysts as cancer theranostics.

Arjun Sabu, Manoj Kandel, Ritwick Ranjan Sarma, Lakshminarayan Ramesan, Ekta Roy, Ramalingam Sharmila, Hsin-Cheng Chiu

Abstract readReview
In one paragraph

Review in APL bioengineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arjun SabuDepartment of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.ORCID https://orcid.org/0000-0001-5514-0762
Manoj KandelDepartment of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.ORCID https://orcid.org/0009-0004-0148-9247
Ritwick Ranjan SarmaDepartment of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.ORCID https://orcid.org/0000-0003-0786-2263
Lakshminarayan RamesanDepartment of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.ORCID https://orcid.org/0000-0001-6427-2003
Ekta RoyDepartment of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.ORCID https://orcid.org/0009-0007-2479-5185
Ramalingam SharmilaDepartment of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.
Hsin-Cheng ChiuDepartment of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan.ORCID https://orcid.org/0000-0001-5509-2107

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer nanotechnology is a promising area of cross-disciplinary research aiming to develop facile, effective, and noninvasive strategies to improve cancer diagnosis and treatment. Catalytic therapy based on exogenous stimulus-responsive semiconductor nanomaterials has shown its potential to address the challenges under the most global medical needs. Semiconductor nanocatalytic therapy is usually triggered by the catalytic action of hot electrons and holes during local redox reactions within the tumor, which represent the response of nontoxic semiconductor nanocatalysts to pertinent internal or external stimuli. However, careful architecture design of semiconductor nanocatalysts has been the major focus since the catalytic efficiency is often limited by facile hot electron/hole recombination. Addressing these challenges is vital for the progress of cancer catalytic therapy. In recent years, diverse strategies have been developed, with heterojunctions emerging as a prominent and extensively explored method. The efficiency of charge separation under exogenous stimulation can be heightened by manipulating the semiconducting performance of materials through heterojunction structures, thereby enhancing catalytic capabilities. This review summarizes the recent applications of exogenous stimulus-responsive semiconducting nanoheterojunctions for cancer theranostics. The first part of the review outlines the construction of different heterojunction types. The next section summarizes recent designs, properties, and catalytic mechanisms of various semiconductor heterojunctions in tumor therapy. The review concludes by discussing the challenges and providing insights into their prospects within this dynamic and continuously evolving field of research.

Identifiers

PMID39381587
PMCPMC11459490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.